Meet with our product experts in one-on-one virtual sessions
Set Up a MeetingDr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.
Therapy Area | Product Name | Dosage Form | EU Approval Status | US Approval Status |
---|---|---|---|---|
Oncology | Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials | Injection | Under review | Approved |
Oncology | Imatinib Mesylate Tablets 100/400 mg | NA | Approved | |
Oncology | Imatinib Mesylate Capsules 50/100/400 mg | Approved | NA | |
Oncology | Docetaxel Injection Concentrate and 80 mg/4 ml | Injection | Approved | Approved |
Oncology | Bendamustine HCl Concentrate for Solution for Infusion 180 mg 4 ml | Approved | NA | |
Immuno Suppressant | Fingolimod 0.5mg | Approved | Approved | |
Oncology | Bendamustine Hydrochloride Injection 25 mg/Vial and 100 mg/Vial | Injection | NA | Tentative Approved |
Oncology | Capecitabine Tablets 500 mg | Approved | Approved | |
Oncology | Capecitabine Tablets 150 mg | Oral | NA | Approved |
Oncology | Fulvestrant Injection 250 mg/5 ml (50 mg/ml) | Injection | Approved | Approved |
Oncology | Everolimus 2.5mg, 5mg & 10mg | Approved | NA | |
Oncology | Dasatinib 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg Film tablet | Under review | Tentative Approved | |
Oncology | Bortezomib For Injection 3.5 mg/vial | Injection | Approved | Approved |
Oncology | Decitabine for Injection 50 mglVial | Injection | NA | Approved |
Oncology | Azacitidine for Inj 100 mg/vial | Injection | Approved | Approved |
Oncology | Lenalidomide Capsules 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg | NA | Approved (2.5, 20 mg) Tentative approved (Other SKUs) | |
Oncology | Pemetrexed, 100 mg, 500 mg, powder for concentrate for solution for infusion (Di Sodium Amorphous) | Approved | Tentative Approved | |
Oncology | Pemetrexed for Injection 100 mg/Vial, 500 mg/Vial, 1g/vial | Injection | NA | Tentative Approved |
Oncology | Pomalidomide Capsules 1mg, 2mg, 3mg and 4mg | NA | Tentative Approved | |
Oncology | Carfilzomib for injection 60mg/vial | Injection | NA | Approved |
Oncology | Palbociclib Capsules, 75 mg, 100 mg and 125 mg | NA | Tentative Approved | |
Oncology | Abiraterone Acetate Tablets 250 mg | NA | Approved | |
Oncology | Melphalan Hydrochloride for Injection, 50 mg Single-Dose Vial | Injection | NA | Approved |
Oncology | Cabazitaxel Injection 60 mg/1.5 ml | Injection | Approved | Approved |
Oncology | Sunitinib Malate | Oral | NA | Approved |
Immuno Suppressant | Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg | NA | Approved | |
Immuno Suppressant | Sirolimus 1 mg and 2 mg | NA | Approved |
Dr. Reddy’s supplies high-quality APIs to leading formulation manufacturers across the world, enabling them to develop affordable medicines for patients worldwide. We are the preferred API partner to pharma companies across the US, Europe, Latin America, Japan, China, Korea and emerging markets.
To enable access to medicines in countries where we are not directly present, we supply the finished products to our partners for them to distribute and commercialize. We offer market specific products and dossiers which meets the local requirements in securing the marketing authorization followed by commercialization. The products and dossiers can be customized as per country requirements.
Research and Development | Manufacturing Faicilities | Nich Product Opportunities | Vertical Integration |
---|---|---|---|
4 State-of-the-art R&D centres in India, U.K., U.S., and Netherlands 1200+ research scientists working on various projects | 11 formulations manufacturing facilities | Peptides, Prostaglandins, HPAPIs, Innovative drug delivery, Novel dosage forms, Complex Injectables | More than 60% of our formulations are backward integrated with our In- house API |
Our 11 formulations manufacturing facilities that are operated in accordance with cGMP (ICH Q7a) and regularly inspected/audited by international regulatory authorities and customers (USFDA, MHRA, EMA, PMDA, TGA, SAHPRA, ANVISA, Russian MoH, CFDA, COFEPRIS and Health Canada).
Dr. Reddy's has an expertise of developing and manufacturing various dosage forms:
Oral Solids | Injectables | Novel Dosage Forms |
---|---|---|
Tablets, Chewable tablets, Orodispersible | Lyophilized product and Liquid solution | Emulsions, Suspensions, Microspheres Liposomes tablets, Capsules, soft gel capsules Pellets a and Nanoparticles |
Highly experienced and integrated technical team to support from filing-to-launch.
Highly experienced technical and global regulatory teams with experience of 350+ Filings and 150+ approvals across B2B markets.
Regulatory services | Tech Transfer support | Bio Study design support |
---|---|---|
Team of regulatory experts | Complete knowledge transfer | Clinical pharmacokinetic team available |
Support filing activities | Support local manufacturing | Design bio study protocol |
Across multiple countries of interest |
Our experts will answer your questions, provide advice, and help you understand our product better
Set Up a MeetingNo information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.